ADARx Pharmaceuticals, Inc.
Research score, not a recommendation.
Market data
Live quote and chart from Yahoo Finance, loaded through this server. Insider purchases are marked on the chart.
–
partial data Market cap is missing; missing inputs count as neutral in the score.
same price, one day All 11 purchases were at $17.00 on 2026-09-28. That pattern also occurs in IPO or conversion subscriptions, which are not open-market conviction buying.
Why this score
Research score: a weighted blend of the five factors, times the routine and offering discounts, minus the selling penalty.
Why are they buying?
No explanation has been generated for this cluster. The filings in the table below are the primary evidence.
Stock Price & Insider Purchase History
Daily close price with open-market insider purchases plotted over time
Loading price history…
| Date | Insider | Role | Shares | Price | Value | Flags | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-28 | George Simeon history of George Simeon's purchases | Director | 1,007,407 | $17.00 avg | $17.1M | ||
| 2026-09-28 | George Simeon | 592,593 | $17.00 | $10.1M | SEC filing for George Simeon (opens in a new tab) | ||
| 2026-09-28 | George Simeon | 414,814 | $17.00 | $7.1M | SEC filing for George Simeon (opens in a new tab) | ||
| 2026-09-28 | SR ONE CAPITAL MANAGEMENT, LLC history of SR ONE CAPITAL MANAGEMENT, LLC's purchases | 10% owner | 1,007,407 | $17.00 avg | $17.1M | ||
| 2026-09-28 | SR ONE CAPITAL MANAGEMENT, LLC | 592,593 | $17.00 | $10.1M | SEC filing for SR ONE CAPITAL MANAGEMENT, LLC (opens in a new tab) | ||
| 2026-09-28 | SR ONE CAPITAL MANAGEMENT, LLC | 414,814 | $17.00 | $7.1M | SEC filing for SR ONE CAPITAL MANAGEMENT, LLC (opens in a new tab) | ||
| 2026-09-28 | ORBIMED ADVISORS LLC history of ORBIMED ADVISORS LLC's purchases | Director | 950,000 | $17.00 avg | $16.1M | ||
| 2026-09-28 | ORBIMED ADVISORS LLC | 588,235 | $17.00 | $10.0M | SEC filing for ORBIMED ADVISORS LLC (opens in a new tab) | ||
| 2026-09-28 | ORBIMED ADVISORS LLC | 61,516 | $17.00 | $1.0M | SEC filing for ORBIMED ADVISORS LLC (opens in a new tab) | ||
| 2026-09-28 | ORBIMED ADVISORS LLC | 300,249 | $17.00 | $5.1M | SEC filing for ORBIMED ADVISORS LLC (opens in a new tab) | ||
| 2026-09-28 | GORDON CARL L history of GORDON CARL L's purchases | Director | 950,000 | $17.00 avg | $16.1M | ||
| 2026-09-28 | GORDON CARL L | 588,235 | $17.00 | $10.0M | SEC filing for GORDON CARL L (opens in a new tab) | ||
| 2026-09-28 | GORDON CARL L | 61,516 | $17.00 | $1.0M | SEC filing for GORDON CARL L (opens in a new tab) | ||
| 2026-09-28 | GORDON CARL L | 300,249 | $17.00 | $5.1M | SEC filing for GORDON CARL L (opens in a new tab) | ||
| 2026-09-28 | Chimovits Erez history of Chimovits Erez's purchases | Director | 61,516 | $17.00 | $1.0M | SEC filing for Chimovits Erez (opens in a new tab) | |
| Total | $67.6M | ||||||
What happened next
A run ends after a pause in the buying, so one company can have several. Returns are the stock's return minus its benchmark's (IWM for small companies, SPY otherwise), from the first open after the run became a cluster. Past results, not a forecast.
After this run became a cluster: 21 days –63 days –126 days –